Worlds Inc (WDDD)

[IBB-99]

About Chris Coughlin, 5.47% owner mentioned in the Statement of Ownership since he is over the 5% threshold:

Background

Mr. Christopher J. Coughlin, also known as Chris, has been an Independent Director at Allergan plc since July 2014 and serves as its Lead Independent Director since October 26, 2016. Mr. Coughlin served as an Advisor to Tyco International Ltd. from 2010 to September 2012. Mr. Coughlin has significant experience in major acquisition, divestiture as well as other types of transactions. He served as the Chief Financial Officer and Executive Vice President of Tyco International plc from March 7, 2005 to December 1, 2010. He served as the Chief Operating Officer of Interpublic Group of Companies, Inc. from June 16, 2003 to December 2004 and served as its Chief Financial Officer from August 2003 to June 2004 and Executive Vice President from August 2003 to December 2004. Mr. Coughlin served as the Chief Financial Officer and Executive Vice President of Pharmacia Corporation from March 2000 to 2003. He joined Pharmacia Corporation in 1998. He served as an Executive Vice President and Chief Financial Officer of Pharmacia & Upjohn LLC (P&U), a subsidiary of Pharmacia from March 1998 to March 2000; President of Nabisco International from 1997 to March 1998 and Executive Vice President and Chief Financial Officer of Nabisco Holdings Corp. from 1996 to 1997. Mr. Coughlin entered the pharmaceutical industry in 1981 when he joined STWB Inc., where, he held a number of management positions, including Vice President of Finance International, Vice President of Worldwide Consumer Healthcare and Chief Financial Officer until 1996. He began his career with Arthur Young & Company. He served as the Chairman of Dun & Bradstreet, Inc. from October 7, 2013 to December 2016 and its Director from December 6, 2004 to May 31, 2017. He served as the Chairman of Dun & Bradstreet Corp. from October 7, 2013 to December 7, 2016. Mr. Coughlin has been a Director of Alexion Pharmaceuticals, Inc. since July 2014. Mr. Coughlin serves as a Director of Mallinckrodt LLC. He served as a Director of Dun & Bradstreet Corp. since December 6, 2004 until May 10, 2017. He served as a Director of Hologic, Inc. from March 2, 2016 to March 27, 2017. He served as an Independent Director of Forest Laboratories, LLC since August 2011. He served as a Director at Perrigo. He served as a Director at Dipexium Pharmaceuticals, LLC from November 2012 to July 3, 2014. He served as a Director of Covidien PLC (Covidien, Ltd) since June 29, 2007 until January 26, 2015. He served as a Lead Independent Director at Dun & Bradstreet from August 2010 to October 7, 2013. He served as a Director of Monsanto Company since March 2000. He served as a Director of Amersham Biosciences Corporation since July 2000. He served as a Corporate Audit Director of STWB Inc. He served as a Director of Interpublic Group of Companies Inc. from July 2003 to December 31, 2004. From 1981 to 1996 he held various positions, including Chief Financial Officer, at Sterling Winthrop. Mr. Coughlin holds a B.S. Degree in Accounting from Boston College in 1974.

Form SC 13G: http://archive.fast-edgar.com//20180521/A8A2P22CZ225J2H2222A22Z2UDMLZZ2242A2/

From Bloomberg: https://www.bloomberg.com/research/stocks/private/person.asp?personId=5555505&privcapId=863120